First-Line Treatment of Patients with Recurrent or Metastatic

Recruiting

18 years - 99 years

All

Phase 3

5 participants needed

1 Location

Brief description of study

This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Metastatic Squamous Cell Carcinoma,Carcinoma
Age: 18 years - 99 years
Gender: All

Male or Female Age 18 or older Metastatic Squamous Cell Carcinoma

Updated on 04 Aug 2024. Study ID: 848499

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

First-Line Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Brief description of study

Eligibility of study

Find a site

Interested in the study